• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Amedisys Inc

    8/14/25 4:45:10 PM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email
    S-8 POS 1 d11643ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on August 14, 2025

    Registration Statement File No. 333-60525 

    Registration Statement File No. 333-51704 

    Registration Statement File No. 333-53786 

    Registration Statement File No. 333-143967

    Registration Statement File No. 333-152359

    Registration Statement File No. 333-182347

    Registration Statement File No. 333-205267

    Registration Statement File No. 333-225461

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-60525)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-51704)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-53786)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-143967)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-152359)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-182347)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-205267)

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-225461)

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Amedisys, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware    11-3131700

    (State or other jurisdiction of

    incorporation or organization)

      

    (I.R.S. Employer

    Identification No.)

    3854 American Way, Suite A, Baton Rouge, LA    70816
    (Address of Principal Executive Offices)    (Zip Code)

    Employee Stock Purchase Plan

    Amedisys, Inc. 1998 Stock Option Plan

    Amedisys, Inc. Directors’ Stock Option Plan

    Amedisys, Inc. Employee Stock Purchase Plan

    Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan

    Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan

    (Full title of the plan)

    Scott G. Ginn

    Chief Financial Officer

    3854 American Way, Suite A

    Baton Rouge, LA 70816

    (Name and address of agent for service)

    (225) 292-2031 or (800) 467-2662

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    Amedisys, Inc., a Delaware corporation (the “Company”), is filing these Post-Effective Amendments (these “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (collectively, the “Registration Statements”) previously filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”), to deregister any and all shares of the Company’s common stock, par value $0.001 per share (the “Company Common Stock”), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof (note that the share numbers listed below do not take into account corporate actions, such as stock splits, taken in the interim):

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-60525), which was filed with the Commission on August 3, 1998, pertaining to the registration of 1,000,000 shares of Company Common Stock under the Employee Stock Purchase Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-51704), which was filed with the Commission on December 12, 2000, pertaining to the registration of 1,425,000 shares of Company Common Stock under the Company’s 1998 Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-53786), which was filed with the Commission on January 16, 2001, pertaining to the registration of 75,000 shares of Company Common Stock under the Company’s Directors’ Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-143967), which was filed with the Commission on June 22, 2007, pertaining to the registration of 2,500,000 shares of Company Common Stock under the Company’s 1998 Stock Option Plan and Employee Stock Purchase Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-152359), which was filed with the Commission on July 16, 2008, pertaining to the registration of 1,862,459 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-182347), which was filed with the Commission on June 26, 2012, pertaining to the registration of 4,100,000 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan and Employee Stock Purchase Plan;

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-205267), which was filed with the Commission on June 26, 2015, pertaining to the registration of 1,500,000 shares of Company Common Stock under the Company’s 2008 Omnibus Incentive Compensation Plan; and

     

      •  

    Registration Statement on Form S-8 (Registration File No. 333-225461), which was filed with the Commission on June 6, 2018, pertaining to the registration of 2,500,000 shares of Company Common Stock under the Company’s 2018 Omnibus Incentive Compensation Plan.

    On June 26, 2023, the Company entered into that certain Agreement and Plan of Merger with UnitedHealth Group Incorporated, a Delaware corporation (“UnitedHealth Group”) and Aurora Holdings Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of UnitedHealth Group (“Merger Sub”), which provides for the merger of Merger Sub with and into the Company, with the Company surviving as a wholly owned subsidiary of UnitedHealth Group (the “Merger”). The Merger became effective on August 14, 2025, pursuant to a Certificate of Merger filed with the Secretary of State of the State of Delaware.

    In connection with the Merger, the Company has terminated any and all of the offerings of the Company’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold or otherwise unissued at the termination of the offerings, the Company hereby amends the Registration Statements and removes from registration any and all of the securities of the Company registered under the Registration Statements that remain unsold or otherwise unissued as of the date of these Post-Effective Amendments, and hereby terminates the effectiveness of each of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Baton Rouge, State of Louisiana, on the 14th day of August, 2025.

     

    AMEDISYS, INC.,
    By:   /s/ Richard Ashworth
    Name:   Richard Ashworth
    Title:   President and Chief Executive Officer

     

    Note:

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

    Get the next $AMED alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amedisys downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

    7/29/24 7:29:37 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys downgraded by William Blair

    William Blair downgraded Amedisys from Outperform to Mkt Perform

    7/1/24 7:29:43 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys downgraded by Truist with a new price target

    Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

    6/7/23 9:03:46 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Amedisys Reports Second Quarter 2025 Financial Results

    BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2025. Three-Month Periods Ended June 30, 2025 and 2024 Net service revenue increased $30.7 million to $621.9 million compared to $591.2 million in 2024.Net income attributable to Amedisys, Inc. of $28.1 million, which is inclusive of merger-related expenses totaling $26.3 million ($26.1 million, net of tax), compared to net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) in 2024.Net income attributable to Amed

    7/29/25 4:45:52 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys Reports First Quarter 2025 Financial Results

    BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

    4/23/25 4:45:43 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Amedisys Reports Second Quarter 2024 Financial Results

    BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

    7/24/24 4:30:52 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Amedisys Reports First Quarter 2024 Financial Results

    BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

    4/24/24 4:45:46 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Financials

    Live finance-specific insights

    View All

    AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

    BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

    5/3/23 4:31:00 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

    All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

    5/3/23 4:30:00 PM ET
    $AMED
    $OPCH
    Medical/Nursing Services
    Health Care

    Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

    BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

    4/20/23 8:00:00 AM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    SEC Filings

    View All

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:39 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:26 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form S-8 POS filed by Amedisys Inc

    S-8 POS - AMEDISYS INC (0000896262) (Filer)

    8/14/25 4:46:15 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Griffin Jennifer G returned 20,173 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:31 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Director Capps Vickie L returned 9,818 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:38 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    Director Kline Teresa L. returned 9,818 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - AMEDISYS INC (0000896262) (Issuer)

    8/14/25 4:02:47 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/13/24 4:58:48 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/12/24 5:24:28 PM ET
    $AMED
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

    SC 13G/A - AMEDISYS INC (0000896262) (Subject)

    2/8/24 10:18:47 AM ET
    $AMED
    Medical/Nursing Services
    Health Care